BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

Mizuho initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $34.00

Jefferies initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $27.00

TD Cowen initiated coverage of Enliven Therapeutics with a rating of Outperform

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

DEF 14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

S-8 - Enliven Therapeutics, Inc. (0001672619) (Filer)

10-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details  Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, inclu

BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a clin

Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., Nov. 13, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small mo

BOULDER, Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m. GMT. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archi

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, pos

BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target th

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ MBC and CRC Strong balance sheet with $312 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generat

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:  Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 5Time: 8:30 a.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, June 10Time: 3:20 p.m. ET Both fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventh

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e